Abstract
COVID-19 is characterized by a large number of asymptomatic and mild cases that are difficult to detect; most of them remain unknown, still having an important role in the transmission of the disease, this makes the pandemic difficult to control. The purpose of this research is to develop an epidemiological model that allows to estimate the number of unknown/asymptomatic cases in a given area. The SEIAMPR system, a novel simulation based model for COVID-19 is designed and implemented in Python. The intuition of the model is simple: about 80% of COVID-19 infected people evolve as asymptomatic or with a mild clinical course, many of them remain unknown to the authorities, some of them including those in critical conditions are eventually detected and classified as positive cases. The simulator reproduces this process using an adaptive method integrated with official data. The simulator has been used for modelling the outbreak in 21 regions in Italy. The positive effects of lockdown policies are demonstrated: unknown active cases 12 days after the lockdown (March the 21th) ranged from 284101 to 374038, e.g. many more than all the official cases in Italy, reducing to 10213/20949 the reopening day. The number of unknown active cases at the beginning of June in the Lombardia region ranged from 6813 to 13390 demanding particular attention. SEIAMPR is simple to tune and integrate with official data, it emerges as an up-and-coming tool for reporting the effect of lockdown measures, the impact of the disease on the population, and the remaining unknown active cases for evaluating the timing of exit strategies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No approval was needed for this reaserch.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
A few typos were corrected. Availability information added.
Data Availability
The used data are available in the Italian Civil Protection site. The source code is available upon request.
